Benzinga
Benzinga
Benzinga
giovedì, settembre 24

Definium Therapeutics Inc

DFTXNASDAQ
Trade with Public
Trade with Public
$36.73
-0.92-2.44%
In chiusura: Sep 24, 5:00 PM EST
$37.17
0.441.2%
Post-mercato: 6:50 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Definium Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Definium Therapeutics (DFTX).

Price Target Range — 3 Quarters

Analyst Consensus — 15 Analysts

15Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$64Upside to Avg. PT+70.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 15, 2026Canaccord GenuitySumant KulkarniPT RaiseBuy$64→$78
Sep 15, 2026Baird Christopher ChenPT RaiseOutperform$75→$79
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79

Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Definium Therapeutics, Maintains $70 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $70 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Definium Therapeutics, Maintains $66 Price Target

Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $66 price target.
Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target

RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperform and maintains $66 price target.
Benzinga Newsdesk

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top analysts changed outlook on top names. See analyst ratings page for all changes.
Avi Kapoor

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved